These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 30543930)

  • 1. PARP inhibitors in ovarian cancer.
    Franzese E; Centonze S; Diana A; Carlino F; Guerrera LP; Di Napoli M; De Vita F; Pignata S; Ciardiello F; Orditura M
    Cancer Treat Rev; 2019 Feb; 73():1-9. PubMed ID: 30543930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
    Lau CH; Seow KM; Chen KH
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE; Kennedy RD
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
    Wang L; Wang Q; Xu Y; Cui M; Han L
    Curr Drug Targets; 2020; 21(2):167-178. PubMed ID: 31553293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer.
    Zheng F; Zhang Y; Chen S; Weng X; Rao Y; Fang H
    Biomed Pharmacother; 2020 Mar; 123():109661. PubMed ID: 31931287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
    Alvarez Secord A; O'Malley DM; Sood AK; Westin SN; Liu JF
    Gynecol Oncol; 2021 Aug; 162(2):482-495. PubMed ID: 34090705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The current status of PARP inhibitors in ovarian cancer.
    McLachlan J; George A; Banerjee S
    Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARP Inhibitors in Ovarian Cancer: A Review.
    O'Malley DM; Krivak TC; Kabil N; Munley J; Moore KN
    Target Oncol; 2023 Jul; 18(4):471-503. PubMed ID: 37268756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
    Sheta R; Bachvarova M; Plante M; Renaud MC; Sebastianelli A; Gregoire J; Navarro JM; Perez RB; Masson JY; Bachvarov D
    J Transl Med; 2020 Nov; 18(1):439. PubMed ID: 33213473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.
    Guo Q; Yang Q; Li J; Liu G; Nikoulin I; Jia S
    Curr Pharm Biotechnol; 2018; 19(14):1114-1121. PubMed ID: 30585545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PARP inhibitors in ovarian cancer.
    Goldlust IS; Guidice E; Lee JM
    Semin Oncol; 2024; 51(1-2):45-57. PubMed ID: 38262776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review on mechanisms of resistance to PARP inhibitors.
    Desai C; Pathak A; Limaye S; Maniar V; Joshi A
    Indian J Cancer; 2022 Mar; 59(Supplement):S119-S129. PubMed ID: 35343196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PARP Inhibitors in Ovarian Cancer.
    Mittica G; Ghisoni E; Giannone G; Genta S; Aglietta M; Sapino A; Valabrega G
    Recent Pat Anticancer Drug Discov; 2018; 13(4):392-410. PubMed ID: 29512470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line PARP inhibitors in ovarian cancer: summary of an
    Banerjee S; Gonzalez-Martin A; Harter P; Lorusso D; Moore KN; Oaknin A; Ray-Coquard I
    ESMO Open; 2020 Nov; 5(6):e001110. PubMed ID: 33310779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer.
    Musella A; Bardhi E; Marchetti C; Vertechy L; Santangelo G; Sassu C; Tomao F; Rech F; D'Amelio R; Monti M; Palaia I; Muzii L; Benedetti Panici P
    Cancer Treat Rev; 2018 May; 66():7-14. PubMed ID: 29605737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Veliparib: a new therapeutic option in ovarian cancer?
    Ghisoni E; Giannone G; Tuninetti V; Genta S; Scotto G; Aglietta M; Sangiolo D; Mittica G; Valabrega G
    Future Oncol; 2019 Jun; 15(17):1975-1987. PubMed ID: 31074636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Latest clinical evidence and further development of PARP inhibitors in ovarian cancer.
    Mirza MR; Pignata S; Ledermann JA
    Ann Oncol; 2018 Jun; 29(6):1366-1376. PubMed ID: 29750420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials.
    Shao F; Liu J; Duan Y; Li L; Liu L; Zhang C; He S
    Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32096544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PARP inhibition as frontline therapy in ovarian cancer.
    Moore KN; Pothuri B; Monk B; Coleman RL
    Clin Adv Hematol Oncol; 2020 Sep; 18(9):550-556. PubMed ID: 33006584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer.
    McCann KE
    Curr Opin Obstet Gynecol; 2018 Feb; 30(1):7-16. PubMed ID: 29251678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.